Iatrogenic Harm & Psychiatric Medication Withdrawal: A Therapist’s Guide to Supporting Clients Through Antidepressant and Benzodiazepine Tapers

/

🎯 A Note Before We Begin

While this article is written mainly as a guide for therapists supporting people through psychiatric medication tapering, withdrawal, and education about psychiatric medication injury, anyone interested in entering the conversation may find the information here useful.

This article explores:

  • The potential benefits and risks of psychiatric medications

  • The physiology of medication dependence and withdrawal

  • How these medications can contribute to nervous system dysregulation

  • The distinctions between addiction, physiological dependence, tolerance, misuse, and abuse

  • How education, informed consent, and therapy can support both providers and consumers of psychiatric medications

This article is not politically affiliated.

I originally published this article several months ago, but am revisiting and expanding it due to the recent and often polarizing attention surrounding psychiatric medication withdrawal, informed consent, and deprescribing conversations in the headlines.

It is also important to clarify that this discussion is not about demonizing psychiatric medications or dismissing the people who benefit from them.

Many individuals experience profound relief, stabilization, and improved quality of life with these medications. Others experience difficult side effects, tolerance, or withdrawal related complications. Both experiences deserve acknowledgment and compassionate discussion.

I am not a doctor, physician, or prescriber.

This topic is deeply important to me, both professionally and personally.

As a therapist, I have witnessed many clients benefit significantly from psychiatric medications. I have also seen individuals experience substantial harm related to long-term use, rapid tapering, withdrawal syndromes, and moderate to severe nervous system destabilization.

This article focuses specifically on how therapists, within their scope of practice, can support clients experiencing difficult antidepressant or benzodiazepine tapering and withdrawal processes, including cases where medications were taken exactly as prescribed.

I have researched this topic extensively and included credible sources and educational resources for those interested in learning more, whether professionally or personally.

This article is also not about being “for” or “against” psychiatric medication. It is about understanding the full picture: the research, the risks, the benefits, the realities of neuroadaptation, and the stories that too often go unheard, particularly among individuals who experience significant challenges during long-term use or withdrawal.

The decisions to take or to taper a psychiatric medication are deeply personal and should be made collaboratively with a qualified and informed medical provider. Do not attempt to discontinue a psychiatric medication on your own without medical supervision.

If psychiatric medications have helped you, that experience is real and valid.

If psychiatric medications have harmed you, that experience is real and valid too.

🧾 Before We Explore Iatrogenic Harm

Here’s a brief, research-based overview of what some commonly prescribed psychiatric medications can possibly do well.

This list is not exhaustive and does not cover every psychiatric medication, but it highlights several evidence-supported benefits associated with antidepressants and benzodiazepines when used appropriately and under medical supervision.

💊 What Antidepressants Do Well: Fast Facts

  • 2 out of 3 people respond positively to antidepressants, compared to 1 in 3 on placebo (Cipriani et al., 2018, The Lancet).

  • Approximately 67% response rates have been demonstrated in adult depression trials involving many SSRIs and SNRIs.

  • Some of the most effective and well-tolerated antidepressants include escitalopram, sertraline, vortioxetine, and desvenlafaxine.

  • For dysthymia (persistent depressive disorder), SSRIs demonstrate significantly higher efficacy than placebo.

  • With structured support, many people successfully discontinue antidepressants without relapse over time.

  • Withdrawal symptoms are common but often temporary. Slow tapering may significantly reduce severity and incidence.

  • Many individuals remain on these medications long-term without major complications, especially when treatment is paired with therapy, lifestyle interventions, social support, and medical monitoring.

💊 What Benzodiazepines Do Well: Fast Facts

  • Rapid anxiety relief with onset often occurring within minutes to hours

  • Effective short-term treatment for acute panic attacks and severe anxiety spikes

  • Helpful for short-term insomnia management

  • Commonly used for procedural sedation in dentistry and surgery

  • Useful for muscle relaxation in acute injuries and neurological conditions

  • Effective rescue medications for seizure disorders

  • Sometimes used as temporary bridge medications while antidepressants take effect

  • Can provide short-term stabilization during periods of acute distress or trauma

🧠 What Is Iatrogenic Injury and How Common is it ?

Iatrogenic injury refers to harm caused by medical treatment itself.

In the context of psychiatric medication, it refers to symptoms or complications that may arise from the medications intended to help, particularly during long-term use, tapering, or discontinuation.

This can include physical, emotional, cognitive, and neurological symptoms that are frequently misunderstood or misdiagnosed.

As a trauma-informed therapist, I have worked with clients who were prescribed psychiatric medications for years or decades without fully understanding the potential for tolerance, neuroadaptation, physiological dependence, or withdrawal.

When these medications are reduced or discontinued, some individuals experience destabilizing symptoms that are often interpreted as relapse or the emergence of a new psychiatric disorder.

Again, this article is not anti-medication.

Many people benefit from psychiatric medications, and for some individuals they are lifesaving.

The goal here is to increase awareness surrounding informed consent, clinician education, trauma-informed care, and compassionate support for those who experience medication-related harm, especially when medications were taken exactly as prescribed.

The Research

One of the most frequently cited reviews on antidepressant withdrawal, conducted by James Davies and John Read (2019), found that approximately 56% of individuals attempting to discontinue antidepressants experienced withdrawal symptoms, with nearly 46% of those individuals describing the symptoms as severe.

The review also noted that withdrawal symptoms sometimes persisted for weeks, months, or longer in a subset of individuals.

The findings of this review helped fuel broader public and clinical discussions surrounding antidepressant withdrawal, informed consent, and deprescribing practices, while also generating controversy and debate within psychiatry regarding methodology, interpretation, and prevalence estimates. Subsequent research has produced lower estimates in some populations, highlighting the complexity and ongoing evolution of this field.

Despite differing estimates, there is now growing consensus across many major medical organizations that antidepressant withdrawal can, in some cases, be significant, prolonged, and clinically destabilizing, particularly after long-term use or rapid tapering.

🌀 Why This Happens: Tolerance, Tachyphylaxis, and Nervous System Disruption

Tolerance

The nervous system adapts to ongoing medication exposure by reducing receptor sensitivity or availability, requiring higher doses to achieve the same effect. This is well described with both antidepressants and benzodiazepines.

Tolerance withdrawal

A term describing a phenomenon in which withdrawal-like symptoms emerge while a person is still taking a medication at a stable dose, rather than after dose reduction or discontinuation.

It is thought to occur when the nervous system has adapted (via receptor downregulation or altered neurotransmitter signaling) to the ongoing presence of a drug to such a degree that the current dose no longer adequately maintains prior equilibrium.

Tachyphylaxis

Sometimes referred to as “antidepressant poop-out,” tachyphylaxis describes a loss of therapeutic effect despite continued use, likely reflecting ongoing neuroadaptive changes in receptor signaling.

Withdrawal

Withdrawal refers to symptoms that emerge during dose reduction or discontinuation. These symptoms reflect rebound and recalibration across multiple neurotransmitter systems, including downregulation (reduction in number or efficiency) of receptors that bind to serotonin, GABA, and glutamate.

Severity and duration vary widely and may, in some cases, persist for months or longer.

Kindling

Kindling describes a sensitization process in which repeated withdrawal episodes become progressively more intense over time, potentially reflecting increased nervous system reactivity.

How These Processes Overlap

Although described separately, tolerance, tachyphylaxis, and withdrawal often represent different phases of the same underlying process: neuroadaptation to chronic pharmacologic exposure.

These processes may present at different times:

  • While still taking the medication (tolerance withdrawal)

  • When effectiveness diminishes (tachyphylaxis)

  • During dose reduction or discontinuation (withdrawal)

  • Or after stopping (protracted symptoms such as PAWS or BIND presentations)

🧠 Shared Symptom Clusters Across All Phases

Across these states, symptoms often cluster in overlapping domains:

Neurological / sensory

Brain zaps, dizziness, tinnitus, sensory hypersensitivity, paresthesias, tremor, internal vibration, akathisia

Cognitive

Brain fog, slowed thinking, memory and attention impairment, word-finding difficulty, dissociation, executive dysfunction

Emotional / psychiatric

Anxiety, panic, depression, irritability, emotional blunting, mood instability, intrusive thoughts, dissociation, depersonalization, derealization

Autonomic / physical

Insomnia, palpitations, GI disturbance, fatigue, temperature dysregulation, flu-like sensations

Neuromuscular

Muscle tension, spasms, weakness, motor restlessness, coordination changes

Multi-Systemic Reactivity (central sensitization and autonomic dysregulation)

Nervous system hypersensitivity and reduced stress tolerance across multiple systems at once is commonly reported when one has reached a state of tolerance withdrawal, downregulation of receptors, and/or during the tapering process. This may include heightened or unusual reactions to medications, vitamins, or supplements that were previously well tolerated, along with difficulty returning to baseline after stress or activation.

This pattern may reflect “central sensitization,” meaning the central nervous system becomes more reactive and amplifies internal and external signals, and “autonomic nervous system dysregulation,” meaning the body has more difficulty smoothly shifting between states of activation (fight or flight) and recovery (rest and digest). This can contribute to emotional destabilization, increased intrusive thoughts, and in some cases increased suicidal ideation.

🧠 PAWS (Post-Acute Withdrawal Syndrome)

A term used to describe persistent or fluctuating symptoms following discontinuation, including anxiety, depression, cognitive impairment, sleep disruption, emotional sensitivity, and reduced stress tolerance. Not formally recognized in DSM-5, but widely described in withdrawal literature.

🧠 BIND (Benzo-Induced Neurological Dysfunction)

A proposed syndrome describing prolonged neurological and physiological symptoms associated with benzodiazepine exposure, including in prescribed use. Reported features include sensory disturbances, akathisia, tinnitus, muscle weakness, emotional blunting, and in severe cases, seizures.

BIND emphasizes potential iatrogenic neurological injury beyond addiction-based frameworks.

🧠 Summary

Across medication classes, these phenomena reflect neuroadaptation: changes in receptor sensitivity and neurotransmitter regulation in response to chronic exposure. When exposure changes, symptoms may emerge across cognitive, emotional, autonomic, and sensory systems.

These experiences do not inherently indicate relapse or addiction, but may reflect nervous system recalibration following pharmacologic adaptation.

🧩 Polypharmacy and Medication Stacking

Polypharmacy is when someone is prescribed multiple psychiatric medications over time, often because new or ongoing symptoms are seen as a return of the original condition or a new diagnosis.

In some cases, these symptoms are actually related to medication effects such as tolerance, withdrawal, or changes in how the nervous system is adapting. But instead of considering that possibility, another medication may be added to treat the new symptoms.

This can lead to a cycle where medications keep getting added over time, while the root cause of the symptoms is not fully explored or addressed. As this happens, it can become harder to tell whether symptoms are coming from the original condition, the medications themselves, or withdrawal effects.

At the same time, care may not always fully include supports such as coping skills, nervous system regulation tools, lifestyle support, strengthening supportive relationships, and access to basics like time outdoors, fresh air, and sunlight.

Over time, some people may find themselves on multiple medications for years and still struggling, particularly when broader supports such as coping skills, nervous system regulation, relationships, and lifestyle factors are not consistently integrated into care alongside medication management.

A more balanced approach includes regularly reviewing medications, considering whether symptoms could be medication-related, and ensuring that psychological support, coping tools, and broader life-based supports are part of care alongside medical treatment.

📊 The Gap Between Clinical Trials and Real-World Use

One major challenge in psychiatric medication research is that many antidepressants are approved based on relatively short-term clinical trials, often lasting approximately 6–12 weeks, while real-world use frequently extends for years or decades.

Researchers including Michael Hengartner have argued that this creates an important gap in our understanding of long-term outcomes, including tolerance, withdrawal, neuroadaptation, and the physiological effects of prolonged exposure.

More recent analyses have also highlighted that few long-term trials systematically monitor withdrawal symptoms, tapering outcomes, or post-discontinuation functioning, despite the increasing prevalence of long-term antidepressant prescribing.

This growing recognition has contributed to increased interest in deprescribing research, hyperbolic tapering approaches, and updated guidance such as the The Maudsley Deprescribing Guidelines.

📉 Why Traditional Tapering Approaches Often Fail

For many years, psychiatric medications were commonly tapered over relatively short periods of time, sometimes days or weeks.

However, emerging research and lived clinical experience suggest that some nervous systems adapt far more extensively to psychiatric medications than previously understood, particularly after long-term use.

This has led to growing recognition of protracted withdrawal syndromes, nervous system sensitization, and the need for slower, more individualized tapering approaches.

Psychiatrists and researchers such as Mark Horowitz, along with clinicians and educators including Anders Sørensen, have helped bring greater attention to these issues through research, clinical education, and patient advocacy.

One major development emerging from this work is the concept of hyperbolic tapering.

🧠 What Is Hyperbolic Tapering?

Hyperbolic tapering is based on the understanding that psychiatric medications do not affect the brain in a linear way.

Small dose reductions at lower doses can create disproportionately large effects on receptor occupancy and nervous system function.

Because of this, tapering often needs to slow down progressively as doses get lower, sometimes involving very small reductions over extended periods of time.

This approach differs significantly from older linear tapering models, which often reduced medications in equal milligram amounts regardless of receptor sensitivity.

The goal of hyperbolic tapering is not to keep people on medications indefinitely, nor to push people off medications prematurely.

The goal is nervous system stability and harm reduction.

📚 The Maudsley Deprescribing Guidelines

The Maudsley Deprescribing Guidelines were developed by psychiatrists and researchers including Mark Horowitz and David Taylor following growing recognition that psychiatric medication withdrawal is often more complex, prolonged, and physiologically significant than previously understood.

Dr. Horowitz has spoken publicly about experiencing severe antidepressant withdrawal symptoms himself after long-term antidepressant use, an experience that helped shape his later research and advocacy work surrounding safer tapering practices and informed consent.

The guidelines focus on the deprescribing and tapering of:

  • Antidepressants

  • Benzodiazepines

  • Z-drugs (such as zolpidem/Ambien and zopiclone)

  • Gabapentinoids

  • Other psychiatric medications associated with physiological dependence and withdrawal syndromes

The guidelines acknowledge several realities that were historically underrecognized:

  • Withdrawal symptoms can sometimes be severe and prolonged

  • Withdrawal may be mistaken for relapse

  • Some individuals require very gradual tapering schedules

  • Nervous system sensitization varies greatly from person to person

  • One-size-fits-all tapering approaches may increase risk of destabilization

Importantly, these guidelines are not anti-medication.

Rather, they represent an effort to improve informed consent, reduce iatrogenic harm, and support safer prescribing and deprescribing practices through more individualized, nervous system-informed care.

🧠 Dependence vs. Addiction vs. Tolerance vs. Misuse vs. Abuse

Language matters.

Many individuals experiencing psychiatric medication withdrawal are inaccurately labeled as “addicted” when their experience is more accurately described as physiological dependence.

Dependence

The body adapts to a medication, and withdrawal symptoms emerge if the medication is reduced or stopped. This can occur during entirely appropriate, prescribed use.

Addiction

Addiction involves compulsive use, craving, behavioral dysregulation, and continued use despite harmful consequences.

Most long-term psychiatric medication users do not meet criteria for addiction. Many clients are criticized and labeled by the very providers that prescribed the medication in the first place, that they are “addicted,” which is erroneous, harmful, and leaves someone with not only wrong information, but without appropriate resources.

Tolerance

Tolerance is a neuroadaptive process in which increasing doses are required to achieve the same therapeutic effect.

Misuse

Misuse refers to taking medication outside prescribed parameters.

Abuse

Abuse involves harmful or hazardous patterns of use that contribute to impairment or risk.

🧠 Myth vs. Clinical Nuance: Addiction, Dependence, and Withdrawal

Myth:
If a medication causes withdrawal symptoms, it must be addictive.

Clinical nuance:
Withdrawal, physiological dependence, and addiction are distinct processes. They overlap in public conversation, but they are not interchangeable in clinical practice or neuroscience.

💊 Antidepressants (SSRIs, SNRIs, etc.)

  • Not considered addictive in the clinical sense

  • Do not typically produce craving, euphoria, or compulsive drug-seeking behavior

  • However, they can produce physiological dependence through receptor adaptation

  • Discontinuation may lead to withdrawal symptoms due to neuroadaptation (including serotonin receptor downregulation and nervous system recalibration)

💊 Benzodiazepines

  • Can produce both physiological dependence and addiction-like patterns in a small subset of users

  • Large epidemiological data suggest low rates of formal use disorder among prescribed users (~1–2%) (Blanco et al., 2018)

  • However, even without addiction, benzodiazepines are strongly associated with tolerance and withdrawal due to GABA-A receptor downregulation

  • Risk increases with duration of use, dosage, and rate of taper

⚠️ Key shared mechanism across medication classes

Regardless of addiction status, many psychiatric medications can lead to:

  • Receptor downregulation or altered receptor sensitivity

  • Neuroadaptive changes in neurotransmitter systems (e.g., serotonin, GABA, glutamate)

  • Tolerance (reduced effect over time at the same dose)

  • Withdrawal symptoms when dose is reduced or discontinued

  • In some cases, prolonged or severe nervous system dysregulation during tapering or discontinuation

These processes reflect physiological adaptation, not characterological weakness or behavioral addiction.

📊 Epidemiological context

Large U.S. population data indicate that approximately 1–2% of individuals prescribed benzodiazepines meet criteria for a substance use disorder, while misuse rates are higher but still represent a minority of users (Blanco et al., 2018). These figures highlight that addiction is not the predominant outcome in prescribed populations, even though physiological dependence and withdrawal effects are more common and clinically significant than once assumed.

🌱 Why Psychotherapy Matters in Psychiatric Medication Tapering

Recent research and clinical deprescribing literature consistently indicate that antidepressant discontinuation outcomes improve when slow tapering is combined with psychological support.

A recent meta-analytic review reported in The Lancet Psychiatry (December 2025 coverage in secondary medical summaries) found that, across data from over 17,000 adults, gradual tapering supported by therapy is associated with better outcomes than tapering alone in reducing the return of symptoms for which the medication was originally prescribed and improving tolerability during discontinuation.

Across studies and clinical guidelines, slower tapering schedules combined with psychological support are associated with fewer and less severe withdrawal effects compared to rapid or unsupported discontinuation. These combined approaches also tend to produce better overall outcomes than medication reduction alone.

Psychotherapy in this context can include validation, education, emotional support, and practical coping skills for daily life. It may also involve mind-body regulation strategies, thought-based coping tools, and exploration of how past experiences may influence current coping patterns and relationships.

This does not suggest that psychiatric medications are always inherently harmful or unnecessary. Rather, it highlights the importance of informed, collaborative, and holistic care that integrates medical oversight with psychological support.

For therapists, this emphasizes the value of being educated in medication tapering and withdrawal phenomena so they can better support clients during these transitions.

For individuals considering tapering, it may also be helpful to reflect on whether structured therapeutic support or an experienced taper support coach could be beneficial during the process.

🧰 What Therapists Can and Can’t Do

Therapists are not prescribers and should not give medical advice about medication changes. However, they play an important role in emotional support, psychoeducation, nervous system stabilization, and coordinated care.

Therapists Can:

• Learn about withdrawal, iatrogenic injury, and medication-related nervous system changes
• Educate themselves and support informed discussion with clients and prescribers
• Validate lived experience without premature pathologizing
• Support nervous system regulation, pacing, and stabilization
• Use trauma-informed and somatic approaches within scope
• Collaborate with prescribers (with consent)
• Share education and resources when appropriate
• Help clients separate physiological symptoms from shame-based interpretations
• Support containment and grounding during high distress or increased suicidal ideation

Therapists Should Avoid:

• Labeling withdrawal or medication effects as relapse by default
• Assuming symptoms are purely psychological
• Minimizing physical or neurological symptoms
• Over-relying on cognitive reframing while ignoring physiology
• Ignoring medication or taper-related contributions to symptoms
• Encouraging medication changes outside prescriber scope
• Dismissing sensitivity to medications, supplements, or stimuli
• Over-pathologizing distress without considering multiple contributing factors

🧩 In Closing

Supporting clients through psychiatric medication withdrawal, especially when iatrogenic harm may be involved, requires humility, curiosity, compassion, and a nervous system-informed lens.

Therapists do not need to have all the answers. But we do need to remain open to emerging research, validate our clients’ experiences, and help connect people to safe, informed support.

By deepening our understanding of medication-related injury, neuroadaptation, withdrawal physiology, and trauma-informed care, we can help reduce harm and better support individuals navigating one of the most misunderstood experiences in modern mental health care.

📚 Psychiatric Medication Deprescribing & Withdrawal Resource Library

This is a curated, non-exhaustive list of clinical, research, and lived-experience resources related to psychiatric medication tapering, withdrawal, and deprescribing. Inclusion does not imply affiliation or endorsement.

🏥 Clinical & Tapering Support Services

The Ashton Manual
Benzodiazepine withdrawal guidance manual developed by Professor Heather Ashton.
https://www.benzoinfo.com/ashtonmanual

Benzodiazepine Information Coalition
Educational and advocacy organization focused on benzodiazepine risks, withdrawal, and informed consent.
https://www.benzoinfo.com

Inner Compass Initiative / The Withdrawal Project
Peer-led educational platform and support resource for psychiatric medication withdrawal.
https://www.theinnercompass.org

Outro Health
Clinical tapering service providing structured deprescribing support for psychiatric medications.
https://www.outro.com

SafeTaper
Clinically informed resource focused on gradual psychiatric medication tapering and withdrawal support.
https://www.safetaper.org

TaperClinic
Clinician-informed services and educational resources focused on psychiatric medication tapering and withdrawal support. https://www.taperclinic.com

True You Psychiatry
Psychiatric practice offering deprescribing support, including individualized tapering strategies and withdrawal-informed clinical care. https://www.trueyoupsychiatry.com

🧠 Advocacy, Education & Research Platforms

Mad in America
Independent platform focused on critical psychiatry research, lived experience perspectives, and medication harm awareness.
https://www.madinamerica.com

National Institute on Drug Abuse (NIDA)
U.S. federal research institute providing definitions and data on addiction, dependence, and substance use science.
https://nida.nih.gov

🧪 Peer-Reviewed Research

Cipriani, A., et al. (2018). The Lancet
Network meta-analysis of antidepressant efficacy in major depressive disorder.

Davies, J., & Read, J. (2019). Addictive Behaviors
Systematic review of antidepressant withdrawal incidence, severity, and duration.

Horowitz, M. A., & Taylor, D. (2019). The Lancet Psychiatry
Introduction of hyperbolic tapering model for SSRIs to reduce withdrawal risk.

Hengartner, M. P. (2020). Therapeutic Advances in Psychopharmacology
Critical review of long-term antidepressant effectiveness and withdrawal confounding in relapse studies.

Lader, M. (2011–2014).
Clinical reviews on benzodiazepine dependence, tolerance, and long-term risk profiles.

Blanco, C., et al. (2018). Journal of Clinical Psychiatry
Epidemiology of benzodiazepine use, misuse, and use disorder in U.S. adults.

Horowitz, M. A., Taylor, D., & Mangin, D. (2024).
The Maudsley Deprescribing Guidelines (Wiley-Blackwell).
Evidence-based guidance for tapering antidepressants, benzodiazepines, gabapentinoids, and Z-drugs.

Cosci, F., et al. (2025). The American Journal of Medicine
Analysis of antidepressant trial duration compared to real-world use patterns.

📖 Practitioner & Patient-Facing Literature

Sørensen, A. (2024). The Why of Withdrawal
Explores antidepressant and antipsychotic withdrawal phenomena and symptom persistence. (Fri Forlag)

Disclaimer

While I am not a medical doctor or prescriber, this article reflects my professional experience as a therapist and my own extensive research on this topic.

This article is not intended to serve as medical advice.

Always consult with a qualified medical provider before making changes to psychiatric medications.

If you are in California and would like to receive therapy support focused on coping during a medication taper, or if you are outside of California and seeking emotional support or skills coaching during a medication taper, you can learn more on my website: www.cecilylongotherapy.com